COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Reports Fiscal Year and Fourth Quarter 2025 Results; Issues 2026 Annual Earnings and Revenue Guidance
04/02/2026
Conference Call and Webcast scheduled for tomorrow, February 5, 2026 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign [...]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
04/02/2026
ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on [...]
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
04/02/2026
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/02/2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the [...]
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
04/02/2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026 [...]
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026
04/02/2026
Daix (France), New York ( États-Unis ), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales [...]
CC Pharma, filiale de Tilray, figure parmi le classement TOP 100 Innovator en Allemagne
04/02/2026
Cette distinction récompense CC Pharma dans son rôle de leader de l’innovation et de partenaire de référence du marché pharmaceutique européen DENSBORN, Allemagne, 04 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la [...]
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
04/02/2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Interim report 2025/26 - Organic growth despite challenges in the North American market
04/02/2026
ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was [...]
ChemoMetec enters Letter of Intent with Roche Diagnostics
04/02/2026
ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating [...]
New NMDP-Sponsored Trial Data Show Comparable Patient-Reported Outcomes and Survival Across Levels of Genetic Mismatch
04/02/2026
ACCESS trial results at the 2026 Tandem Meetings reinforce mismatched unrelated donors as safe, effective and well-tolerated option Practice-advancing research conducted through CIBMTR demonstrates collaborative, [...]
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
04/02/2026
Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it [...]
SAFE - Croissance de 6,5 % du chiffre d’affaires 2025 - Confirmation de la feuille de route
04/02/2026
Croissance de 6,5 % du chiffre d’affaires 2025 Confirmation de la feuille de route Fleurieux-sur-l’Arbresle - France - le 4 février 2026 à 18h. Safe Group publie son chiffre d’affaires annuel consolidé pour l'exercice [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ la société pharmaceutique de [...]

Pages